Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9317327 | 0.92 | LMNA (0.47) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL3020914 | 0.91 | LMNA (0.38) | LMNACYP2C19HIF1A | |
| SCHEMBL9356454 | 0.89 | LMNA (0.48) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL3024600 | 0.88 | LMNA (0.44) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL3026646 | 0.87 | LMNA (0.36) | LMNA | |
| SCHEMBL9318639 | 0.86 | LMNA (0.38) | LMNA | |
| SCHEMBL3016225 | 0.84 | LMNA (0.40) | LMNACYP2C19HIF1A | |
| SCHEMBL709956 | 0.84 | LMNA (0.33) | LMNA | |
| SCHEMBL3013388 | 0.83 | LMNA (0.50) | LMNACYP2C19HIF1A | |
| SCHEMBL3026469 | 0.83 | LMNA (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200971-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2013-04-24 | — | — | EP | disclosed |
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| EP-2200655-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-07-18 | — | — | EP | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| EP-2231200-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-09-29 | — | — | EP | disclosed |
| US-20100233097-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-16 | — | — | US | disclosed |
| US-20100221192-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100221192-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-09-02 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| EP-2205553-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-07-14 | — | — | EP | disclosed |
| EP-2200971-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-06-30 | — | — | EP | disclosed |
| EP-2200655-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009060021-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009047316-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047318-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009005364-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189656-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | LMNA 1835/4885CYP2C19 4234/4885HIF1A 1213/4885 |
| US-20100221192-A1 | CONTRAST AGENTS | C5, C1S, C1R | LMNA 1840/4885CYP2C19 2570/4885HIF1A 1051/4885 |
| US-20100233097-A1 | CONTRAST AGENTS | C1R, C3AR1, CNKSR1 | LMNA 1939/4885CYP2C19 3512/4885HIF1A 825/4885 |
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | LMNA 2025/4885CYP2C19 2823/4885HIF1A 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.